Roche announced it will acquire PathAI for $750 million upfront, aiming to expand AI-powered capabilities in digital pathology workflows. The deal targets PathAI’s technology used by pathology laboratories and biopharma teams, positioning Roche to integrate machine-learning tools closer to routine diagnostic decision-making and translational development.